Eupraxia Reaches Its Target Enrollment Of 120 Patients In Phase 2b Placebo-Controlled Blinded Portion Of RESOLVE Trial

• Eupraxia reached its target enrollment of 120 patients in the Phase 2b placebo-controlled blinded portion of the RESOLVE trial
   
• The Company has a statistical team who are doing periodic reviews of the unblinded data to ensure that the statistical assumptions and sample size on efficacy are adequate and do not need to be revised. These reviews have confirmed that the sample size as designed does not need to be adjusted
   
• Within both parts of the RESOLVE trial (open-label Phase 1b/2a and placebo-controlled Phase 2b), over 3,000 injections of EP-104GI or vehicle have been administered with no treatment-related Serious Adverse Events (SAEs)
   
• Interim analysis of the Phase 2b portion of the study is on track for December 2026
   

VANCOUVER, British Columbia, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the ongoing RESOLVE study evaluating the safety and efficacy of EP-104GI for the treatment of Eosinophilic Esophagitis ("EoE") has reached its enrollment target.